Nang Kuang Pharmaceutical Co., Ltd. Stock

Equities

1752

TW0001752004

Pharmaceuticals

End-of-day quote Taiwan S.E. 18:00:00 2024-04-25 EDT 5-day change 1st Jan Change
44.55 TWD -0.11% Intraday chart for Nang Kuang Pharmaceutical Co., Ltd. +1.02% -16.42%

Financials

Sales 2022 1.94B 59.56M 81.32M Sales 2023 2.15B 66M 90.11M Capitalization 5.38B 165M 226M
Net income 2022 352M 10.8M 14.75M Net income 2023 198M 6.08M 8.3M EV / Sales 2022 3.33 x
Net Debt 2022 6.62M 203K 278K Net Debt 2023 327M 10.04M 13.71M EV / Sales 2023 2.66 x
P/E ratio 2022
18.4 x
P/E ratio 2023
27.2 x
Employees 552
Yield 2022
3.6%
Yield 2023
3.75%
Free-Float 44.45%
More Fundamentals * Assessed data
Dynamic Chart
Nang Kuang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Nang Kuang Pharmaceutical Co., Ltd. Announces Changes in Chief Internal Auditor CI
Nang Kuang Pharmaceutical Co., Ltd. Appoints Pen-Sung Chen as Corporate Governance Officer CI
Nang Kuang Pharmaceutical Co., Ltd. Announces Resignation of Wen-Yung Tsai as Spokesperson, Financial Officer, Accounting Officer and Corporate Governance Officer CI
Nang Kuang Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Nang Kuang Pharmaceutical Co., Ltd.(TWSE:1752) added to S&P Global BMI Index CI
Nang Kuang Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Nang Kuang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Nang Kuang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Nang Kuang Pharmaceutical Co., Ltd. Appoints Wen-Yung Tsai as Corporate Governance Officer CI
Nang Kuang Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Nang Kuang Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Nang Kuang Pharmaceutical Co., Ltd. Receives Final U.S. FDA Approval for Its ANDA CI
Nang Kuang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Nang Kuang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
More news
1 day-0.11%
1 week+1.02%
Current month-5.11%
1 month-5.61%
3 months-8.90%
6 months-16.73%
Current year-16.42%
More quotes
1 week
44.10
Extreme 44.1
45.20
1 month
43.85
Extreme 43.85
47.50
Current year
43.85
Extreme 43.85
54.30
1 year
43.85
Extreme 43.85
83.00
3 years
32.60
Extreme 32.6
85.70
5 years
28.80
Extreme 28.8
85.70
10 years
28.15
Extreme 28.15
85.70
More quotes
Managers TitleAgeSince
Chief Executive Officer - 02-08-31
Director of Finance/CFO - 10-07-31
Chairman - 05-07-09
Members of the board TitleAgeSince
Director/Board Member - 14-06-24
Chairman - 05-07-09
Chief Executive Officer - 02-08-31
More insiders
Date Price Change Volume
24-04-26 44.55 -0.11% 111,210
24-04-25 44.6 -0.67% 54,859
24-04-24 44.9 +0.45% 72,475
24-04-23 44.7 +1.25% 128,379
24-04-22 44.15 +0.11% 171,203

End-of-day quote Taiwan S.E., April 25, 2024

More quotes
NANG KUANG PHARMACEUTICAL CO., LTD. is principally engaged in the manufacture, processing and trading of western medicine. The company main products include injections, sterile injections, powder injections, hard capsules, bare ingots, film ingots, casing ingots, granules and creams, among others. The Company is also engaged in the manufacture, processing and trading of medical equipment. The Company distributes its products within the domestic market and to overseas markets.
Calendar
More about the company

Quarterly revenue - Rate of surprise